Articles

Software innovations help researchers decode immune complexity in cancer.

Mastering data preparation is key to harnessing the full potential of advanced computational tools.

How can researchers and laboratories best leverage digital technologies for faster drug development?

As scientific output grows, the risk of a promising drug getting lost increases, but advances in artificial intelligence and machine learning may prevent that.

Learn strategies to maintain data integrity, optimize analytical methods, and stay compliant with evolving regulations. 

Effective target identification is central to drug discovery, but finding the right drug target is not as simple as it may seem in theory. 

New imaging flow cytometry technology lets researchers look at their flow sorted cells in real time and spot key cellular properties. 

Scientists recovered movement in mouse models of spinal cord injury.

Take a look into the making of the DDN Dialogues podcast episode: From warhead to cancer-killer, the quest for more actinium-225.

Specialized cells in omental adipose tissue may repress fat cell development.

A new type of drug for schizophrenia could finally be approved in September. Others may not be far behind.

Researchers discovered an immunological connection between the eye and the brain that could lead to new therapeutics for central nervous system diseases.

A modular CAR T cell could make cancer therapy safer and more effective.

Research misconduct poisons the well of scientific literature, but finding systemic ways to change the current “publish or perish” culture will help.

A gene therapy targeting excitatory neurons significantly reduced seizures in a mouse model of the most common cause of child epilepsy.

Researchers halted sperm production in mice using an existing drug, offering hope for a future male contraceptive pill.

By making peptides ring shaped, researchers uncovered a new class of drugs that is “just right” for previously undruggable targets.

Paolo Martini leads the biotech company’s rare disease research program with the hope of developing the very first treatments for genetic metabolic disorders.

As an alternative to daily pills, a new RNAi drug could lower blood pressure with a twice-yearly injection.

The best scientific presentations are not just about the science. The delivery matters too.